Sarepta Therapeutics (SRPT) PT Lowered at Piper Sandler After a 'Voluntary Pause Of Elevidys'

Piper Sandler analyst Biren Amin lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $11.00 (from $18.00) while maintaining a Neutral rating.

The analyst commented: "Sarepta Agrees To Complete Voluntary Pause Of Elevidys; This evening, SRPT announced a voluntary and temporary pause in Elevidys shipments, effective at the close of business on July 22, 2025. This decision is intended to provide the company with the necessary time to address any information requests and facilitate the completion of the Elevidys safety labeling supplement process in collaboration with the FDA. Join us this Wednesday at 10am for a webinar with the Founding President and CEO of PPMD to discuss how the DMD patient community is responding to the latest safety events."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Critical One Energy closes second tranche of flow-through placement
• Stripe, Advent In Talks To Buy Paypal - WSJ